Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. (not Palvela Therapeutics, Inc., as indicated in the metadata) on September 22, 2016, covering events occurring on September 20, 2016. The filing reports the election of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change reported is the appointment of Christopher Kiritsy as a Class I Director. Key details of this appointment include:
- Term: Expires at the 2018 annual meeting of stockholders.
- Background: Mr. Kiritsy is the President and CEO of Arisaph Pharmaceuticals, Inc., a co-founder of Arisaph, and previously held executive roles at Kos Pharmaceuticals, Inc.
- Compensation Package:
- Stock Option: Granted a non-statutory option to purchase up to 30,000 shares of common stock.
- Exercise Price: $1.59 per share (closing price on the date of grant).
- Vesting: Equal quarterly installments following the date of grant, subject to continued service.
- Cash Retainer: Annual cash retainer of $25,000.
- Indemnification: An indemnification agreement was entered into to cover expenses, judgments, fines, and settlement amounts arising from his service as a director.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, or specific risk factors beyond the standard indemnification agreement. The document confirms there are no undisclosed arrangements or transactions in which Mr. Kiritsy has a material interest.
Investor Verification Checklist
- Verify the correct registrant name is Pieris Pharmaceuticals, Inc. (metadata listed Palvela Therapeutics, Inc. incorrectly).
- Confirm the vesting schedule and exercise price ($1.59) of the 30,000 share option granted to the new director.
- Review the attached Exhibit 99.1 (Press Release dated September 22, 2016) for additional context on the board expansion.
- Check the Company's Non-Employee Director Compensation Policy to ensure the $25,000 retainer aligns with standard terms for other directors.